Aerie Pharmaceuticals (NASDAQ: AERI)
Some price data may be temporarily unavailable.
Aerie Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Aerie Pharmaceuticals Company Info
Aerie Pharmaceuticals is a biotechnology company that engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of ophthalmic diseases. The company was founded in 2005 and is headquartered in Bridgewater, New Jersey with research facilities in Research Triangle Park, North Carolina. Aerie Pharmaceuticals, Inc. is a former subsidiary of Duke University Medical Center.
News & Analysis
Why Aerie Pharmaceuticals Was Soaring so High This Week
You'd vault skyward, too, if a big-pocketed company were willing to spend a lot of coin on acquiring you.
Is Aerie Pharmaceuticals a Buy?
Wall Street has given the eye-care specialist the cold shoulder in 2020. Is that an opportunity for individual investors?
So Your Biotech Announced Positive Phase 3 Results? Celebrating Could be Premature
Success in clinical trials doesn't guarantee success on the market.
Here's Why Aerie Pharmaceuticals Jumped as Much as 14.4% Today
The eye-care company reported better-than-expected fourth-quarter 2019 product revenue.
Can Aerie Pharmaceuticals Go From 1.5% of the Glaucoma Market to 40%?
Disappointing early sales results for its newest treatments, Rhopressa and Rocklatan, haven't shaken the company's confidence. Wall Street is a different story.
Why Aerie Pharmaceuticals Crashed 22.4% Today
Slow sales of its glaucoma drugs is forcing management to cut its sales guidance.
Is Aerie Pharmaceuticals a Buy?
The small-cap company's shares have fallen 64% in the last year, but a promising drug portfolio might signal an opportunity for investors with a long-term mindset.
Here's Why Aerie Pharmaceuticals Rose as Much as 21.8% Today
A new slide deck shows reasons for optimism.
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.